RHO-KINASE IN PATIENTS WITH ATHEROSCLEROSIS: EFFECTS OF STATINS

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。所列机构为 中心，不一定是研究者的机构。 本研究的目的是研究阿托伐他汀（立普妥）和瑞舒伐他汀（可定），FDA批准的药物，通常由医生处方，以降低胆固醇，对血小板，白色血细胞的某些功能，和动脉血流调节的影响。 这很重要，因为我们正在寻找更有效地预防动脉粥样硬化和心脏病的方法。 许多研究表明，这些药物在减少炎症和稳定斑块方面是有效的。 我们有兴趣更好地了解这些药物对炎症的影响及其作用机制。 这是一项研究者发起的研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to investigate the effects of atorvastatin (Lipitor) and rosuvastatin (Crestor), FDA approved drugs commonly prescribed by doctors to lower cholesterol, on certain function of platelets, white blood cells, and blood flow regulations by arteries. This is important because we are looking at ways to more effectively prevent atherosclerosis and heart disease. Many studies have demonstrated that these drugs are effective at reducing inflammation and stabilizing plaques. We are interested in better understanding the effects of these medicines on inflammation and the mechanism by which they act. This is an investigator initiated study.